Gilead Sciences nears $2B deal for Ouro Medicines - FT

Gilead Sciences nears $2B deal for Ouro Medicines - FT
4 stocks to watch on Monday: MRK, DPZ, GILD, HON
Gilead Sciences to buy Arcellx in deal worth up to $7.8B
4 stocks to watch on Friday: EXPE, MNST, GILD, BA
Gilead Sciences agrees to pay $202 million to settle claims of kickbacks to doctors for HIV drug prescriptions
Gilead Sciences posts higher Q2 profit and revenue on increased sales
197.4BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US3755581036
CUSIP
375558103
Sector
Healthcare
Industry
Drug Manufacturers - General
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
2.35
Book Value
9.53
Dividend Share
3.22
Dividend Yield
2.02%
Earnings Share
-2.65
Wall Street Target Price
160.19
EPS Estimate Current Year
-0.45
EPS Estimate Next Year
9.91
EPS Estimate Current Quarter
-7.2468
EPS Estimate Next Quarter
2.2068
Most Recent Quarter
-
Revenue TTM
30,456,999,936
Gross Profit TTM
24,245,000,192
EBITDA
14,600,999,936
Profit Margin
-10.64%
Return On Assets TTM
14.09%
Return On Equity TTM
-20.68%
Revenue Per Share TTM
24.513
Qtly Revenue Growth YOY
10.20%
Diluted Eps TTM
-2.65
Qtly Earnings Growth YOY
54.80%
Trailing PE
0.00
Forward PE
16
Price Sales TTM
6.7423
Price Book MRQ
16.6893
Enterprise Value Revenue
7
Enterprise Value EBITDA
122
186.63
7.05%490.00
3.18%1416.74
3.09%149.49
2.24%294.85
1.67%60.84
1.03%160.35
0.22%160.00
-0.62%273.48
-0.62%485.98
-0.32%Curated watchlists where GILD is featured.